NCT07741643尚未招募1 期
Phase I Open-Label Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 30
- 主要终点
- Record and evaluate the number events considered clinically significant Grade ≥2 AEs that are considered possibly, probably, or definitely related to [¹⁸F]NOTA-ABY-030, pan800, or both agents.
研究概览
简要总结
The goal of this clinical trial is to learn whether using two imaging agents-Panitumumab-IRDye800 (Pan800) and[18F]NOTA-ABY-030-is safe and feasible for helping surgeons identify tumors and cancer-containing lymph nodes during surgery in adults with head and neck squamous cell carcinoma (HNSCC) who are scheduled for tumor removal and neck dissection.
The main questions it aims to answer are:
- Is the combination of Pan800 and [18F]NOTA-ABY-030 safe and well tolerated in patients undergoing surgery for HNSCC?
- How accurately can Pan800 and [18F]NOTA-ABY-030 detect tumor tissue and cancer-positive lymph nodes when compared with final pathology results?
This is a single-arm, open-label study, so there is no comparison group.
Study Related Steps:
- Receive an intravenous infusion of Pan800 1-2 days before surgery.
- Receive an intravenous injection of[18F]NOTA-ABY-030 on the day of surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years.
- •Subjects diagnosed with any T stage or N stage squamous cell carcinoma and any subsite within the head and neck that are scheduled to undergo surgical resection and neck dissection. Subjects with recurrent disease or a new primary will be allowed.
- •Have acceptable hematologic status, kidney function, and liver function including the following clinical results:
- •Hemoglobin ≥ 9 gm/dL
- •White blood cell count > 3000/mm3
- •Platelet count ≥ 100,000/mm3
- •Serum creatinine ≤ 1.5 times upper reference range
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment.
- •Evidence of QTcF prolongation on ECG within 30 days of pan800 administration (greater than 480 ms).
- •History of infusion reactions to monoclonal antibody therapies.
- •History of allergies to iodine.
- •Pregnant or breastfeeding.
- •Magnesium or phosphorus lower than the normal institutional values and the patient is symptomatic.
- •Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
- •Subjects with history or evidence of interstitial pneumonitis or pulmonary fibrosis.
- •Severe renal disease or anuria.
结局指标
主要结局
Record and evaluate the number events considered clinically significant Grade ≥2 AEs that are considered possibly, probably, or definitely related to [¹⁸F]NOTA-ABY-030, pan800, or both agents.
时间窗: Up to 30 Days
次要结局
未报告次要终点
研究者
Eben Rosenthal
Barry and Amy Baker Professor and Department Chair
Vanderbilt University Medical Center
相似试验
招募中
早期 1 期
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical ProceduresPituitary AdenomaBrain CancerAcoustic NeuromaMeningiomaGlioblastomaNCT07493447Eben Rosenthal30
招募中
1 期
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid TumorsNCT07630961Novartis Pharmaceuticals66
招募中
1 期
First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic CancerMetastatic Prostate CancerCancerMetastatic Breast CancerNCT07608848Integrated Haematology and Oncology Network20
招募中
1 期
An Imaging Study of Anti-GD2-800CW in Patients With NeuroblastomaNeuroblastomaNCT07399821Princess Maxima Center for Pediatric Oncology22
招募中
1 期
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)NCT07460765Vanderbilt-Ingram Cancer Center40